One Year on a GLP-1: The Honest Month-by-Month Shape of It

A year ago I assumed weight loss on a GLP-1 went down in a straight, polite line.

It doesn't. Twelve months in, what I have isn't a tidy slope but a curve with three distinct moods: a queasy, scale-doesn't-move beginning, a stretch in the middle where the real loss happened, and a long flat shelf at the end that nearly talked me into quitting. If you're a few months into Wegovy or Ozempic and Googling whether your particular month is normal, this is the map I wish someone had handed me before I started reading my own year backward from a single percentage.

One ground rule first: every clinical number here comes from published trials, not my bathroom scale. I'm not going to tell you how many kilos I lost, because my body isn't a study and neither is yours. What I can do is lay the year I lived over the data we have and show you where the two line up. The drug, for the record, was semaglutide — sold as Wegovy for weight management and as Ozempic for type 2 diabetes. Same molecule, different dose, same manufacturer. The FDA cleared the obesity version back in June 2021, and that one fact settled me more than anything, because it meant there was real evidence under all the noise.

The first weeks were about the nausea, not the scale

Month one, the scale barely moved. The nausea, on the other hand, introduced itself loudly.

I'd braced for the number to drop on day three. Instead I got a low, seasick queasiness that showed up on a tiny starting dose and parked itself there for a couple of weeks. This tracks with what STEP 1 — the big semaglutide trial everyone quotes — found: the most common side effects were gastrointestinal, nausea and diarrhea at the top of the list, and the trial described them as typically transient, usually mild to moderate, and most likely to fade as the body adjusts and the dose climbs in small steps.

That word transient did a lot of work. It was the difference between "this is my life now" and "this is week two."

Here's the part the panic posts drown out: yes, more people on semaglutide than placebo quit over stomach side effects — but the rate was 4.5% versus 0.8%. So the queasiness was common, and the share who walked away over it stayed small. Most people who felt rotten early did not, in the end, stop.

That slow climb up the dose ladder — the thing r/Ozempic affectionately calls "starting dose gang" — isn't a delay to muscle through. It's the design giving your gut a vote. I treated the low weeks as a waiting room before the "real" dose. Looking back, the waiting room was the treatment.

If the nausea hasn't settled after a couple of weeks, that's a call to your prescriber, not a reason to grit your teeth in private. Holding at your current dose, or climbing slower, sorts it out for a lot of people. Toughing it out alone was never the plan the trial was built around.

So that was the start: not weight loss, exactly. More like negotiating a truce with my own stomach.

Months three to six, where the real loss lived

If month one was the toll booth, months three through six were the open highway.

This is the stretch the average is built on. In STEP 1, adults on semaglutide 2.4 mg lost a mean of 14.9% of their body weight over 68 weeks — a little over a year and a third — against 2.4% on placebo. Strip out the placebo effect and the slice you can credit to the drug itself comes to roughly 12.4 percentage points. That number didn't arrive on day one. It accumulated, and most of the visible momentum, for me and for plenty of people I've compared notes with, landed in this middle window once the dose was up and the gut had stopped filing complaints.

For the first time, the curve had a slope you could see week to week. Clothes shifted before the scale did. The mirror got there before the number. It was, frankly, the most encouraging stretch of the whole year — and also the one that set a trap, because I started assuming this pace was permanent.

A thing worth saying out loud, because nobody told me: this momentum isn't a reward for effort. It's mostly the drug and your own biology doing their thing while the dose sits at its target. Which is exactly why the next part stung the way it did — I'd started taking private credit for the slope, so when it flattened, it felt personal.

The plateau that felt like failure but wasn't

Somewhere in the back half of the year, the line went flat. And I spiraled.

For about three weeks the scale read the same number, give or take the noise of water and sodium and a salty dinner. After months of watching it move, the stillness felt like a verdict. I had done nothing differently. The dose was the same. The food was the same. And yet the open highway had turned into a parking lot.

What I know now, and what would've saved me a fortnight of doom-scrolling: a plateau is one of the most ordinary things a weight curve does. The body adjusts. Loss is never linear, on a drug or off one, and a flat stretch is not the same as a stalled treatment. The STEP 1 curve itself bends and slows on its way to that 14.9% — it doesn't march down at a constant rate and then stop on a dime. A shelf in the line is the shape of the thing, not a crack in it.

A plateau is information, not a sentence. It usually means your body has found a new set point for now — not that the medicine quit, and not that you did. Before you panic-quit over a flat fortnight, that's a conversation to have with your prescriber, who can tell the difference between a normal pause and a reason to revisit the plan.

The community has a name for this too — "month three stall is a thing, push through" is practically a liturgy on the GLP-1 forums. The specifics of which month vary by person, but the experience is near-universal: the line flattens, the brain catastrophizes, and the people who quit right there often quit at the exact moment a little patience would have paid off. I almost became one of them over a number that hadn't budged in twenty days.

What the clinical average quietly hides

Here's the thing about that 14.9% figure — the STEP 1 trial average at week 68, around a year and a third in: it's an average, and an average is one number standing in for a thousand different bodies.

STEP 1 didn't just report a mean. It reported how many people crossed specific lines — and that spread, not the single number everyone repeats, is the honest story.

Run your eye down the middle column. About 86% lost at least 5%. Roughly 69% cleared 10%. And right around half — 50.5% — reached 15% or more. Half the people on the identical drug at the identical dose hit the big number, and the other half didn't. That gap isn't willpower or moral fiber. It's biology nobody got to choose.

So if your year lands lighter than the average, you are not failing the drug, and the drug is not failing you. You're a data point in a wide distribution, same as everyone in that trial. The kindest thing the responder table did for me was retire the idea that 14.9% was a debt I owed the universe. It's the upper-middle of a spread, and where you fall in it is mostly out of your hands.

This is also where I'd gently push back on the before-and-after reel running through your head. The trial reports a range of outcomes for a reason. Some people in that study landed close to where the placebo group did. Comparing your real curve to a stranger's highlight clip is the fastest way to feel like a failure at something you're doing perfectly fine.

Food noise going quiet, the change no scale could show

The biggest shift of my year never showed up as a number anywhere.

A lot of us carry a constant low hum — the running negotiation about the next snack, the second helping, the thing calling from the cupboard at 9 p.m. Somewhere in the early months, people describe that hum going strangely silent. The clinical phrase is reduced appetite. The lived version, the one r/GLP1 christened "food noise," is that the volume drops to near zero and the silence is almost disorienting at first.

It landed for me on an ordinary weekday. I'd skipped lunch without noticing, and the realization startled me, because forgetting to eat had never once been in my repertoire.

By month twelve, this was the change I'd have fought hardest to keep — more than any inch off the waistband. Two honest caveats, though, because this isn't magic:

• It's a tool, not a personality transplant. The silence hands you room to make different choices. It doesn't make them for you.
• It can fade if the medicine stops, right alongside the appetite — which loops straight into the next, and biggest, thing I got wrong.

What surprised me at the one-year mark wasn't the smaller body. It was realizing how much of my head had been rented out to food for years, without my ever sending an eviction notice.

The thing I got wrong: year one isn't a finish line

I spent month eleven half-planning my exit. STEP 4 is the trial that talked me out of it.

In STEP 4, everyone started on semaglutide. After 20 weeks, half kept going and half were switched to placebo without knowing it. The group that stayed on it lost a further 7.9% of body weight over the weeks that followed. The group that stopped regained 6.9%. The gap between continuing and stopping came to about 14.8 percentage points — and about half of that gap was the regain in those who stopped (6.9 points), and the other half was the continued loss in those who stayed on (7.9 points). Both halves point the same way: the medicine was doing the work.

Read that twice, because it's the whole year in one line. Stopping wasn't neutral. Stopping put the car in reverse.

This is managing a chronic condition, not finishing a cleanse. The biology that pushes weight back up doesn't get cured in twelve months. It gets held in check for exactly as long as you keep holding it — which is a very different thing to plan around.

I'd walked into year one half-expecting a hard season and then a ribbon to cross. STEP 4 took that fantasy apart without ceremony. For most people, a GLP-1 behaves more like blood-pressure medication than a course of antibiotics: it works while you take it, and the effect loosens its grip when you don't. That isn't a knock on the drug. It's just what the data says, and knowing it at month one rather than month eleven would have changed how I budgeted, how I planned, and how I talked to my doctor — about the years, not the weeks.

None of which means you're chained to it forever. It means that if and when you stop, that's a decision you make with a clinician and a plan — not something you drift into because a refill lapsed and life got busy. Year two starts with that conversation, not with a victory lap.

Safety lines I kept in view all year

A few non-negotiables rode shotgun the whole twelve months, and they belong on the table before the first dose, not discovered at month nine.

Semaglutide for weight management carries a boxed warning — that's the language on the US FDA label — for thyroid C-cell tumors. It's contraindicated, a flat no, for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or a condition called Multiple Endocrine Neoplasia type 2 (MEN 2). That's not a weigh-the-pros-and-cons item. It's a stop sign, and it's the first thing a careful prescriber asks about. Worth flagging, too: that boxed warning and the approval details are framed by the US FDA, and the approved status, indications, and labeling can read differently wherever you happen to live — so your local regulator and your own prescriber are the ones who know what applies to you.

A couple of other signals I carried in my back pocket all year:

On the pancreas point specifically: acute pancreatitis has been observed in people on GLP-1 medicines, semaglutide included, and the guidance is that treatment should be stopped if it's suspected. Severe, stubborn stomach pain is not "just the side effects" — it's a same-day call, not a wait-and-see.

The most useful thing I did before month one wasn't research. It was an unhurried sit-down with a clinician who read my history out loud. The injection is the easy part. The screening is the part that keeps the whole year safe.

What I'd tell someone at month one

If I could rewind to the person staring at the pen, queasy and impatient, I'd keep it short.

The first month is about your stomach, not the scale, and the slow dose climb is doing its job — don't read the flat number as failure. The real loss tends to show up in the middle months once the dose is up, so judge the trend by the month, not the morning. A plateau is coming, it's normal, and on the forums it's a moment a lot of people seem to quit — often, by their own telling, right before the line moved again. And the 14.9% you keep reading — the STEP 1 average at week 68, around a year and a third — is an average wearing the costume of a promise: half the trial cleared 15%, half didn't, and where you land is mostly biology you didn't pick.

Three boring habits I'd start in week one instead of month three:

1. Protein first. A smaller appetite makes under-eating protein shockingly easy to miss. Reach for it before anything else on the plate.
2. Some resistance, not just walking. Fast loss takes muscle along with fat unless you give your muscles a reason to stay. Bands, bodyweight, dumbbells — whatever you'll actually keep doing.
3. Plan for year two on day one. STEP 4 made the long road plain; budget and plan for a relationship, not a sprint.

The drug quiets the room. What you do with the quiet is still yours.

Where year two begins

Twelve months in, the headline I'd hand my past self isn't a number. It's a shape.

Year one was a curve, not a line — a queasy start, a middle where the loss happened, and a plateau that scared me far more than it should have. The average everyone quotes is real and it's an average, which means your year may look different and still be working. The food noise dropping to silence turned out to matter more to me than any figure on the scale. And the part I most needed to hear at month one is the part a single percentage hides: this was never a finish line. The weight came back in the trial the moment the medicine stopped, so year two is a plan, not a celebration.

None of this is a prescription, and none of it replaces the conversation that decides anything. Everything here comes from published clinical trials and the approved label — the part where you and a doctor who knows your history map out the next twelve months is the part no article can do for you. If a GLP-1 is already part of your life, year two is worth walking into on purpose, with someone who can see the whole curve. That's where I'm starting mine.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app